Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

SUZHOU, China, July 30, 2024 /PRNewswire/ -- On July 29, 2024, Porton Advanced Solutions ("Porton Advanced") announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd ("Geneseed Biotech"). Both sides will combine their respective strengths in the field of gene therapy to jointly provide better drug development services. Leveraging Porton Advanced's end-to-end cell and gene therapy CDMO service platform and resource advantages, combined with Geneseed Biotech's comprehensive core patented technologies in circRNA drug concept validation and process development, the two companies will jointly propel technological innovation and clinical translation, thereby accelerating the implementation of innovative circRNA therapies.

Proton Advanced is committed to providing end-to-end CDMO services for cell and gene therapy, and has extensive experience in nucleic acid therapy process development and GMP production, covering various types including mRNA, saRNA, circRNA, and more. Porton Advanced can provide comprehensive CMC services from preclinical to clinical production. Geneseed Biotech, relying on its profound technology and robust original R&D capability, has broken through the technical bottleneck of circRNA drug development and possesses independent intellectual property rights over its core circularization technology. In this cooperation, both parties will establish a comprehensive strategic partnership to deeply expanding technological cooperation and resource sharing in the field of circRNA. This will further strengthen Porton Advanced's end-to-end CDMO platform, from innovation in research and technology to high-quality project delivery, thereby providing more valuable services to customers.

 "We are very pleased to have entered into a strategic collaboration with Porton Advanced." said Liu Ming, founder and CEO of Geneseed Biotech. "CircRNA is recognized by the industry to be the next-generation RNA platform for vaccines, rare disease therapies, and anti-tumor therapies due to its high stability, low immunogenicity and cost-effective production in drug development. As a pioneering leader in circular RNA research and development, Geneseed Biotech has consistently delved deep into this area, ranging from scientific research to drug development, catering to the evolving demands of our customers. Porton Advanced possesses extensive service experience and profound technical expertise in CGT. Our collaboration across the industrial chain can fully leverage each other's professional and resource strengths, facilitating the development of circRNA drugs and accelerating the industrialization of circRNA technology."

"Collaborating with upstream and downstream enterprises across the industrial chain to realize win-win cooperation and deliver more valuable services to our customers is the core significance of Porton Advanced's efforts in constructing a vibrant CGT ecosystem." said Chen Hui, CFO of Porton Advanced. "We are delighted to forge a strategic partnership with Geneseed Biotech, an excellent CRO enterprise. Geneseed Biotech possesses robust and innovative RNA synthesis technologies, coupled with extensive project experience and platform advantages in the scientific research and application translation of circRNA. By integrating our respective technological strengths and platform resources, we aim to further refine and enhance platform capabilities of Porton Advanced, providing comprehensive CRDMO solutions for the development of innovative RNA therapeutics from early-stage research to clinical and commercial production, empowering our global customers."

About Porton Advanced

Founded in 2018, Porton Advanced is a subsidiary of the globally recognized CDMO Porton Pharma Solutions Ltd. (SZSE Stock Code 300363). Located in Suzhou, China, Porton Advanced offers a cGMP-compliant manufacturing platform for plasmids, cell therapy, gene therapy, and mRNA therapy, enabling different development stages for global companies.

Porton Advanced operates on a "Customer First" approach to cell and gene therapy (CGT) manufacturing, anchored by its core principles of "Compliance, Expertise, and Open Collaboration". The company operates to rigorous, internationally harmonized Quality Management and IP protection standards, bringing innovative manufacturing solutions to the complex challenges in the CGT space. For more information about Porton Advanced, please visit: www.portonadvanced.com.

About Geneseed Biotech

Guangzhou Geneseed Biotech. Co.,Ltd., founded in June 2010 and headquartered in Guangzhou Science City, is a pioneer in circRNA scientific research and application transformation. Geneseed is firmly grounded in robust and reliable RNA synthesis innovation technology, consistently empowering subdivisions from bench to bedside. Geneseed has broken through the technical bottleneck of circRNA drug development and independently developed two RNA circularization strategies --circPrecise® (based on Group I intron self-splicing) & circPure® (based on T4 Rnl2). Relying on the original research and development capability, Geneseed has established multiple technology platforms -- gene synthesis, raw material synthesis, high-throughput sequencing, and bioinformatics analysis, which can provide one-stop services covering drug screening, sequence design, process development, analytical method development, large-scale production, quality control, and raw material preparation. Geneseed is committed to providing biopharma with full-process solution CRDMO solution from early R&D to commercial production. For more information about Geneseed Biotech, please visit: www.geneseed.com.cn/en/

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

BRUSSELS, Sept. 17, 2024 /PRNewswire/ -- The global clean hydrogen project pipeline is growing and maturing, with a sharp increase in projects reaching final investment decision (FID), according to the Hydrogen Council's latest analysis of more than 1,500 projects worldwide. At the same time, the pace and scale of deployment need to accelerate dramatically to meet global climate goals.

The Hydrogen Insights 2024 report, released today and co-authored by McKinsey & Company, reveals that while the global project pipeline has grown by a factor of seven since 2020 from 228 projects to 1,572 projects, as of May 2024, it has also matured, with a strong focus on advancing projects towards execution. Most notably, clean hydrogen projects that reached FID have also seen a seven-fold increase in committed investment, growing from approximately USD 10 billion across 102 projects in 2020 to some USD 75 billion across 434 projects in 2024.

The most recent data from October 2023 to May 2024 further underscores a clear shift from project planning to implementation. Total announced investments through 2030 have increased by approximately 20% – from USD 570 billion to USD 680 billion. The most notable growth has occurred in the more advanced stages of project development, with investments past FID growing by a remarkable 90%, followed by a 30% increase in front-end engineering design (FEED) stage projects.

This clear shift across the global project pipeline from announcements to implementation is coupled with natural attrition that fosters industry maturation by eliminating less viable projects and prioritising those with the highest potential, a pattern also seen in the early stages of other clean energy industries such as wind and solar.

Jaehoon Chang, President and CEO of Hyundai Motor Company and Co-Chair of the Hydrogen Council, said: "The seven-fold increase in committed capital for hydrogen projects reaching FID over the past four years demonstrates the industry's progress. We are pleased to see the industry walking the talk at this critical transitional moment, as evidenced in the latest Insights report. Moreover, further action is needed to ensure an accessible and affordable hydrogen supply, enabling the widespread adoption of hydrogen."

Despite progress, the hydrogen sector, like other clean energy industries currently, faces macroeconomic headwinds including rising inflation and interest rates, as well as geopolitical tensions affecting energy markets. Sector-specific issues such as regulatory uncertainty and increasing costs for renewable power and electrolysers have led to project delays, particularly for renewable hydrogen projects.

Ivana Jemelkova, CEO of the Hydrogen Council, said: "This report sends a clear message: hydrogen is happening. Now that hydrogen is a reality in the energy transition, it's time to drive significantly more investment by 2030 to meet our mid-century targets. Equipped with concrete lessons learned from the past four years, we must urgently address challenges in key markets and create a more favourable environment for project execution."

Sanjiv Lamba, CEO of Linde and Co-Chair of the Hydrogen Council, said: "Realising hydrogen's full climate and socio-economic potential requires a united effort from governments and industry. With a supportive regulatory framework and targeted incentives, investors will have the certainty they need to move projects to FID – ultimately contributing to achieving global climate targets."

About Hydrogen Insights
Hydrogen Insights is the Hydrogen Council's regularly published perspective on the hydrogen industry's evolution. It summarises the current state of the global hydrogen sector and actual hydrogen deployment. Authored by the Hydrogen Council in collaboration with McKinsey & Company, the report draws on a combination of public information and proprietary data from Hydrogen Council members and represents a collaborative effort to share an objective, holistic, and quantitative perspective on the status of the global hydrogen ecosystem.

About The Hydrogen Council
The Hydrogen Council is a global CEO-led initiative with a united vision and long-term ambition for hydrogen to accelerate the clean energy transition. It brings together a diverse group of 140 companies from 20 countries across Americas, Europe, Africa, the Middle East and Asia Pacific. Spanning the entire value chain, and including large multinationals, innovative start-ups as well as investors, the Council's membership represents some $9 trillion in market capitalization, 6.8 million in FTEs and some $6.4 trillion in revenues.

The Council is committed to unlocking the sustainability potential of clean hydrogen, fostering business and technological innovation as drivers for sustainable growth, creating quality jobs and delivering social value. Using its global reach to promote collaboration between industry, governments, investors, and the civil society, the Council provides insights on and pathways for accelerating the deployment of hydrogen ecosystems around the world. It also supports the development of international safety and sustainability standards, paving the way for the deployment of reliable hydrogen solutions at scale.

To find out more visit www.hydrogencouncil.com and follow us on X @HydrogenCouncil and LinkedIn. 

Media Enquiries
Joanna Damerell, Communications Manager, Hydrogen Council
Joanna.damerell@hydrogencouncil.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Global hydrogen industry reports $75 billion in committed capital but climate targets at stake due to project delays